27 February 2024 in Journal of Open Source Software
We present DeepRank2, a deep learning (DL) framework geared towards making predictions on 3D protein structures for variety of biologically relevant applications. Our software can be used for predicting structural properties in drug design, immunotherapy, or designing novel proteins, among other fields. DeepRank2 allows for transformation and storage of 3D representations of both protein-protein interfaces (PPIs) and protein single-residue variants (SRVs) into either graphs or volumetric grids containing structural and physico-chemical information. These can be used for training neural networks for a variety of patterns of interest, using either our pre-implemented training pipeline for graph neural networks (GNNs) or convolutional neural networks (CNNs) or external pipelines. The entire framework flowchart is visualized in Figure 1. The package is fully open-source, follows the community-endorsed FAIR principles for research software, provides user-friendly APIs, publicly available documentation, and in-depth tutorials.
22 January 2025 in bioRxiv
Identifying tumor peptides that bind patient MHC proteins and elicit immune responses is central to immunotherapy, yet progress remains limited to a handful of well-studied alleles. Structure-based methods generalize better than sequence-only models but are constrained by the high computational cost of 3D modeling. We present SwiftMHC, the fastest structure-based framework for peptide–MHC (pMHC) modeling and binding affinity prediction. SwiftMHC predicts peptide–MHC binding in 0.009 sec/case in batch mode on a single A100 GPU—nearly an order of magnitude faster than leading sequence-based methods such as NetMHCpan 4.1 (0.081 sec/case)—while performing competitively in predictive accuracy. In addition to affinity estimation, SwiftMHC generates all-atom 3D pMHC structures and achieves a median Cα-RMSD of 1.32 Å against X-ray benchmarks, matching or better than the accuracy of state-of-the-art approaches (e.g., AlphaFold with fine-tuning) but running thousands of times faster (excluding disk-writing time). These results demonstrate the power of task-specific AI trained on physics-derived synthetic data to overcome the scarcity of experimental structures. Optimized for HLA-A*02:01 9-mers but readily extensible to other alleles, SwiftMHC enables rapid and accurate identification of peptides distinct from self at T-cell–exposed surfaces. This capability may expand immunotherapy targets, improve the safety of TCR-based therapies, and accelerate the development of next-generation cancer immunotherapies.
31 March 2026 in Cell Reports Methods
We developed SwiftMHC, an ultra-fast and accurate structure-based framework for peptide-MHC (pMHC) modeling and binding affinity prediction. Using task-specific deep learning trained on physics-derived synthetic data, SwiftMHC predicts pMHC binding affinities in 0.009 s per case on a single A100 GPU when running in batch mode, offering improved speed compared with leading sequence-based tools such as netMHCpan and MHCflurry while maintaining competitive accuracy. In addition, SwiftMHC generates all-atom 3D pMHC structures with a median Cα-RMSD of 1.32 Å against crystallographic benchmarks, matching or exceeding state-of-the-art methods such as AlphaFold2-finetune but at a lower computational cost. Optimized for HLA-A∗02:01 9-mer peptides but readily extensible to other alleles, SwiftMHC unites structural insight with high-throughput scalability to accelerate safe and effective epitope discovery in cancer immunotherapy.